are changing. As a community, we must work together to use these resources wisely, to learn from outcomes with new therapies and diagnostic tools, to assure all patients can achieve improved care and outcomes regardless of disease state or country of origin.
| INTRODUC TI ON

For it was taught: If she circumcised her first child and he died (as a result of bleeding from the operation) and a
second one died (similarly), she must not circumcise her third child. 1 The existence of a bleeding disorder in males has been recognized since the 2nd century AD. Initially termed "haemorrhaphilia" in 1828 by Hopff and Schonlein, it was later shortened to haemophilia. 2 PWH with ~150, 000 HA and 30, 000 HB; 3% of HA and 5% of HB patients were female. Females with levels ≤40%, defined as PWH, may require intermittent or ongoing haemostatic therapy. 3 Females experience specific haemostatic challenges related to menstruation, pregnancy and other gynaecologic events. Defining the optimal haemostatic level required to achieve bleed suppression or prevention is complex and varies based upon level of deficiency, age and sex. Adding to this complexity is the challenging management of patients with inhibitors, specifically in HB. Globally, there are a reported 4711 FVIII and 280 FIX inhibitor patients. 
R E V I E W A R T I C L E
Optimizing bleed prevention throughout the lifespan: Womb to Tomb S. Gupta | A. D. Shapiro
The ability to define optimal care in haemophilia is influenced by local economies and resources with a vast range of essential replacement therapies available throughout the world; many areas continue to experience product scarcity for even on-demand treatment. There is a pressing need to close the gap between developing and developed nations.
In non-resource-limited settings, there exists an opportunity to strive for a bleed-free life allowing PWH to achieve their full potential. The advent of longer lasting infusion products and innovative agents provides a panoply of resources to achieve this goal; gene therapy may offer a cure within our lifetime.
Development of optimal bleed prevention guidelines requires expert use of available agents integrated with prompt diagnosis, education, knowledgeable ongoing care and development of individualized care plans adjusted to patient age, activity and personal needs.
| OP TIMAL B LEED PRE VENTI ON: DEFINING THE OP TIMAL HAEMOS TATI C LE VEL TO PRE VENT B LEED ING E VENTS
Prophylaxis is defined as the regular infusion of clotting factor concentrates to prevent bleeding events and is the standard of care since the 1990s in developed countries; maintenance of trough levels above 1% modify the severe phenotype to a moderate deficient state. 4 The rate of breakthrough bleeding events on prophylaxis is influenced by targeted trough levels, variations in pharmacokinetics, physical activity and joint status. 5, 6 The level of FVIII/FIX required in severe haemophilia to achieve optimal bleed prevention is not firmly established; 1 regimen does not fit all. New data challenges a 1% trough and demonstrates that levels of 15% or higher may be required to prevent subclinical bleeding events and influence joint outcome; each 1 percent level increase is associated with an 18% reduction in haemarthrosis. [7] [8] [9] However, even intensive prophylactic regimens may not completely prevent mild ankle arthropathy as shown in Swedish and
German patients followed over 25 years. 10, 11 These data may support the need for higher trough levels when achievable. Detailed PK analyses are time-consuming, costly and often not practical. 12 Utilization of product-specific Bayesian PK models, such as in the WAPPS-Hemo system, may surmount this obstacle. 13, 14 Although targeted troughs above 1% clearly confer increased protection against bleeding events, the ability to achieve these are limited by the half-life of the infusion product, the need for repetitive frequent dosing and the associated cost per unit increase in trough achieved. In resource-constrained settings, on-demand therapy, or reduced dose and/or frequency of prophylactic regimens are more commonly utilized.
To optimize bleed prevention, knowledge of the life stage and associated common bleeding events, and individual needs must be addressed comprehensively ( Figure 1 ). circumcision is delayed until care is established with a haemophilia treatment centre (HTC). Neonatal bleeding events are more common in severe deficient patients. 27 Many events are avoided with prompt diagnosis.
Optimally within the first month of life, new families with an affected infant have an educational session with knowledgeable staff.
This educational session reviews the signs and symptoms of a bleed, safe administration of vaccinations, overall child safety measures including use of car seats, seat belts, home childproofing, knowledge of when to seek medical attention, a list of numbers for contact of the HTC team, closest emergency facility for care if required, and the choice and home supply of replacement factor product; antifibrinolytics may be provided. This information is reinforced and expanded throughout life.
| Infants and toddlers
Regular contact with the HTC is maintained to reinforce education.
A comprehensive HTC with an expert and dedicated multidisciplinary team provides best outcomes and lowest mortality. 28 Interval visits every 3-6 months in the first year are helpful for presumptive counselling and planning for replacement therapy initiation. Interval visits are extended based upon care plan, patient age and parental knowledge. Data from the United States CDC's Universal Data
Collection system revealed that 81% of 547 babies bled in the first 2 years of life, including soft tissue (56%), oropharyngeal (41%) and minor head trauma (37%). 22 Knowledge of these events assists education and planning. Oral bleeding due to injury is common in toddlers and can result in significant anaemia requiring urgent medical attention. Alerting families to early recognition of all bleeding events and the need to contact care providers is essential.
As children become mobile the potential for bleeding events, especially musculoskeletal bleeds, increases. The median age for the first joint bleed is 1.8 years. 29 Optimally, primary prophylaxis is initiated in early childhood in the absence of documented joint disease, before the second clinically evident joint bleed, and before 3 years. 30 Overall, joint health is best maintained with prophylaxis initiated at age 2 years or earlier. [31] [32] [33] [34] The importance of prophylaxis was conclusively demonstrated in a prospective randomized controlled trial including joint MRIs in young boys: over a 4-year study period, 7% of patients on every other day prophylaxis developed arthropathy vs 45% on intensive episodic treatment. 9 A variety of prophylactic regimens have been reported by Dutch, Swedish and Canadian groups with varying doses and intervals to suppress bleeding events and limit the development of joint disease while considering economic impact. 4, [33] [34] [35] [36] Although primary prophylaxis is the standard of care recommended by the WHO and WFH, several studies have demonstrated that secondary prophylaxis started after 2 or more joint bleeds, but before the onset of joint disease is also effective to reduce haemorrhage frequency and hospitalization, and improve quality of life. 4, 30, [37] [38] [39] [40] [41] Determination of an achievable optimal trough level to optimally suppress bleeding events requires knowledge of currently available products, individual response and pharmacokinetics, ability to administer replacement therapy and adhere to the regimen, and ongoing careful follow-up that personalizes care throughout all life phases.
Included in ongoing follow-up is the need for identification of sequelae such as inhibitor development. Inhibitor risk is highest in the first 20 exposure days (EDs) and decreases but remains after 50
EDs. 42 The CANAL and RODIN studies revealed a lower inhibitor risk in the prophylactic group supporting early prophylaxis initiation at 10 months. [43] [44] [45] Prompt identification of inhibitors is critical for early intervention and bleed suppression.
Venous access in young children is a significant challenge. 
| Young children to young adults
Ongoing prophylaxis is critical in all age groups to preserve joint health and achieve a normal quality of life. 51 In the United States, <50% of the patients adhere to prescribed regimens.
52,53
| Self-infusion and adherence
Self-infusion is encouraged early; by 6-7 years of age, children are often able to master many aspects of the process. Home/selfinfusion and therapy adherence improve outcomes. 54 
| Transitioning teens to adults
Young adults are 6 times more likely to be non-adherent when following their prophylaxis regimen compared to adolescents. 57 Myriad issues hinder adherence in adolescence and young adults including gaps in patient knowledge of the management of their bleeding disorder and product dosing/administration, self-infusion independence, coverage/payment for care, academic performance, employment opportunities, access to skilled adult care providers/centres, self and peer perception and parental ability to encourage independence. 58 Transition guidelines have been proposed to support transition to adult care providers and to promote independence, education and self-advocacy. 59 
| Young adults to older age
Continuation of prophylaxis into adulthood is considered standard of care to limit long-term joint damage. In many countries, primary prophylaxis at a young age is unavailable. The SPINART study
showed that tertiary prophylaxis (treatment initiation after the onset of joint disease at any age) led to decreased pain and bleeding in older patients with pre-existing joint damage. 30, 60 In the ageing population, patient and age-specific factors affect prophylaxis continuation. Considerations include diminished activity, joint health, poor venous access and availability of infusion assistance (eg, home nursing care, assisted living facilities or proximity of HTCs). Compounding these issues, decreased bone density, visual impairment and muscle weakness may lead to an increased fall risk and serious bleeding events. 61, 62 Individualized care plans are essential to tailor therapy to meet each patient's needs.
| Comorbidities
Many patients who received non-virally inactivated blood products in the 1980s and 1990s have chronic comorbidities, including HIV, HBV and HCV. Although HBV and HCV may be eradicated, the presence of these diseases complicates haemophilia management, as subspecialty care and additional medications are required. 63 Cardiovascular disease (CVD) management is challenging, as anticoagulants, antiplatelet agents and cardiac surgery increase bleeding risk. 64, 65 Therefore, assessment and control of associated CVD risk factors are paramount in this population.
| General considerations throughout the lifespan
Exercise is beneficial for haemophilia patients as it promotes healthy joints, muscle tone, optimal body weight, bone density and quality of life. 66, 67 This is especially important for teens and young adults.
Guidelines on exercise and sports participation have been published by the National Hemophilia Foundation (NHF). 68 Some studies have found ~65% of haemophilia patients to be Vitamin D deficient; low vitamin D levels have a strong association with osteoporosis in haemophilia patients. 69 Additionally, obesity is a rising problem contributing to increased factor consumption and negatively impacting joint health by increasing bleeds and immobility. 39 
| HAEMOPHILIA B LEED PRE VENTION: WHAT IS THE OP TIMAL HAEMOS TATI C PRODUC T ?
Many products are available to treat or prevent bleeding events, ranging from desmopressin for mild HA, cryoprecipitate and FFP, to purified plasma-derived and recombinant FVIII and FIX products.
Cryoprecipitate and FFP are not commonly virally inactivated and therefore not recommended; in addition, FFP may not achieve an adequate haemostatic level and may lead to volume overload and adverse reactions. WFH guidelines recommend replacement of only the deficient factor, effectively advocating the use of highly-purified plasma-derived or recombinant products. 82 Over the past several years, technological advancements have resulted in extended half-life (EHL) products (Table 1 ). The impact on FVIII half-life prolongation is less marked (~1.5X) than that of FIX, which is more pronounced (3-5X) and hence, may result in dosing regimens of up to every other week.
A severe consequence of factor administration is inhibitor formation (~30% incidence in severe HA, ~5% severe HB). A variety of identified factors contribute to inhibitor development. The rate of inhibitor development in HA with recombinant products has been controversial. The SIPPET study reported increased inhibitor development with recombinant compared to plasma-derived products. 83 Upon EMA data review, no clear or consistent evidence of a difference in inhibitor risk between plasma-derived and recombinant products was found. 84 Prompt identification of an inhibitor and discussion of further treatment options including use of bypassing agents, immune tolerance or novel agents, all contribute to ongoing bleed suppression. 85 Emicizumab's success in the paediatric population, specifically in previously untreated patients could be transformative and allow early initiation of therapy to effectively suppress bleeding events while foregoing issues related to venous access, a major obstacle to deliver optimal therapy in this population. Questions will emerge as the use of this agent for HA without inhibitors become available, including when to expose children to FVIII, inhibitor incidence if exposure is delayed etc. Other investigational products in clinical development include fitusiran, TFPI inhibitors and APC inhibitors ( Table 2) .
| Transformative products
86-88
| Gene therapy
Although the introduction of a product in HA that may offer up to a once-monthly dosing regimen would be transformative, bleeding events may intermittently occur. Recent developments in gene therapy pave the way towards achieving a cure in both HA and HB (Table 3 ). Gene therapy in HB has undergone more study due to the AAV capsid capacity and FIX cDNA size. Some successful advantage in children. 92 The use of gene therapy in patients with underlying liver disease, AAV antibodies or FVIII/FIX inhibitors is unclear.
The potential for insertional mutagenesis remains a small but real risk.
| HAEMOPHILIA B LEED PRE VENTION: WHAT C AN B E DONE FOR INHIB ITOR PATIENTS?
Patients with HA low responding inhibitors (peak titre < 5 BU) may be treated with additional FVIII for bleeding events; high responding FVIIa (rFVIIa). Studies have shown both to be effective in treating breakthrough bleeds; both are able to reduce the incidence of bleeds and improve quality of life when used in a prophylactic regimen. 94, 95 The FENOC study suggested aPCC and rFVIIa had similar overall efficacy; however, patient response to a specific BPA can vary over time necessitating a change in therapy. 96 Historically, BPAs were viewed as having unpredictable efficacy; this unpredictability may lie more with the heterogeneity of bleeding events and the diversity of the patient population, rather than the BPA itself. 97 In many countries, inhibitor eradication with immune tolerance induction (ITI) is the standard of care. Although often a prolonged process, a recent study suggested that initiating ITI early in inhibitor TA B L E 2 Emerging biologics in development for the treatment of haemophilia A and B formation rather than waiting for the titre to decrease to <10 BU, can reduce median ITI duration from 3.8 to 1.1 years (P = .03). 98 As morbidity and mortality are increased for inhibitor patients, accelerated inhibitor ablation can translate to improved long-term outcomes.
It is important to screen patients routinely for inhibitors; testing at least annually regardless of number of ED is recommended. (Table 2) .
86-88,102-104
| CON CLUS ION
Haemophilia is a lifelong disorder that requires multidisciplinary expert care tailored to each life stage to optimize bleed prevention and achieve a normal life. The requirements to achieve optimal bleed suppression are demanding for patients, families and care providers. Replacement therapy is expensive and unequally available throughout the world. The potential exists to achieve improved trough levels through use of current and emerging therapies; the associated cost must be weighed by patients, caregivers and society. Over decades, HTC care providers have amassed tremendous knowledge of disease manifestations and required care, as well as the treatment of non-haemophilia related medical issues during each life phase; all interventions beyond replacement therapy must be leveraged to achieve optimal bleed suppression and outcome. Novel agents and gene therapy will advance and transform current care paradigms, yet bring new challenges and questions. HTCs and their care providers will continue to play an integral role to optimize care. The haemophilia community is at the forefront of therapeutic advances. Patients and their dedicated caregivers walk hand in hand towards a promising horizon.
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